BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman Sells 660 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 660 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $16,803.60. Following the transaction, the chief financial officer now owns 120,960 shares in the company, valued at $3,079,641.60. This trade represents a 0.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Price Performance

BLFS stock opened at $26.25 on Thursday. The business has a 50 day moving average price of $26.67 and a 200 day moving average price of $25.48. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on BLFS. Craig Hallum boosted their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Benchmark restated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp increased their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, TD Cowen raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $29.43.

Institutional Trading of BioLife Solutions

Several large investors have recently bought and sold shares of the company. Invesco Ltd. boosted its holdings in BioLife Solutions by 1.1% in the fourth quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock valued at $84,097,000 after acquiring an additional 36,176 shares during the last quarter. Fred Alger Management LLC grew its holdings in shares of BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock worth $41,386,000 after acquiring an additional 16,274 shares during the last quarter. State Street Corp lifted its position in shares of BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares in the last quarter. Millennium Management LLC increased its holdings in shares of BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after purchasing an additional 377,111 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of BioLife Solutions by 4.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock worth $23,028,000 after acquiring an additional 40,416 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.